Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00487329 | Breast | Precancer | gland development | 49/1080 | 436/18723 | 6.11e-06 | 1.73e-04 | 49 |
GO:00018898 | Breast | Precancer | liver development | 21/1080 | 147/18723 | 1.08e-04 | 1.96e-03 | 21 |
GO:00610088 | Breast | Precancer | hepaticobiliary system development | 21/1080 | 150/18723 | 1.45e-04 | 2.49e-03 | 21 |
GO:00016678 | Breast | Precancer | ameboidal-type cell migration | 47/1080 | 475/18723 | 2.19e-04 | 3.35e-03 | 47 |
GO:00486087 | Breast | Precancer | reproductive structure development | 43/1080 | 424/18723 | 2.36e-04 | 3.56e-03 | 43 |
GO:00614587 | Breast | Precancer | reproductive system development | 43/1080 | 427/18723 | 2.75e-04 | 4.00e-03 | 43 |
GO:00454444 | Breast | Precancer | fat cell differentiation | 26/1080 | 229/18723 | 7.60e-04 | 9.04e-03 | 26 |
GO:19908303 | Breast | Precancer | cellular response to leukemia inhibitory factor | 13/1080 | 94/18723 | 2.83e-03 | 2.49e-02 | 13 |
GO:19908233 | Breast | Precancer | response to leukemia inhibitory factor | 13/1080 | 95/18723 | 3.11e-03 | 2.64e-02 | 13 |
GO:0046661 | Breast | Precancer | male sex differentiation | 19/1080 | 165/18723 | 3.14e-03 | 2.65e-02 | 19 |
GO:0008584 | Breast | Precancer | male gonad development | 17/1080 | 141/18723 | 3.15e-03 | 2.65e-02 | 17 |
GO:0046546 | Breast | Precancer | development of primary male sexual characteristics | 17/1080 | 142/18723 | 3.39e-03 | 2.84e-02 | 17 |
GO:004873214 | Breast | IDC | gland development | 64/1434 | 436/18723 | 3.47e-07 | 1.74e-05 | 64 |
GO:004860812 | Breast | IDC | reproductive structure development | 60/1434 | 424/18723 | 2.71e-06 | 1.03e-04 | 60 |
GO:006145813 | Breast | IDC | reproductive system development | 60/1434 | 427/18723 | 3.41e-06 | 1.24e-04 | 60 |
GO:000166714 | Breast | IDC | ameboidal-type cell migration | 64/1434 | 475/18723 | 6.65e-06 | 2.05e-04 | 64 |
GO:000188913 | Breast | IDC | liver development | 24/1434 | 147/18723 | 3.29e-04 | 4.92e-03 | 24 |
GO:0008406 | Breast | IDC | gonad development | 32/1434 | 221/18723 | 3.64e-04 | 5.23e-03 | 32 |
GO:006100813 | Breast | IDC | hepaticobiliary system development | 24/1434 | 150/18723 | 4.46e-04 | 6.04e-03 | 24 |
GO:0045137 | Breast | IDC | development of primary sexual characteristics | 32/1434 | 227/18723 | 5.85e-04 | 7.44e-03 | 32 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARID5B | SNV | Missense_Mutation | | c.3266C>T | p.Ser1089Leu | p.S1089L | Q14865 | protein_coding | tolerated(0.05) | benign(0.089) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ARID5B | SNV | Missense_Mutation | rs758661473 | c.193A>C | p.Thr65Pro | p.T65P | Q14865 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-D1-A0ZP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
ARID5B | SNV | Missense_Mutation | novel | c.2887N>C | p.Ser963Pro | p.S963P | Q14865 | protein_coding | deleterious(0) | possibly_damaging(0.69) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARID5B | SNV | Missense_Mutation | novel | c.2278N>G | p.Ser760Gly | p.S760G | Q14865 | protein_coding | tolerated(0.06) | benign(0) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
ARID5B | SNV | Missense_Mutation | novel | c.102A>C | p.Arg34Ser | p.R34S | Q14865 | protein_coding | deleterious(0) | benign(0.075) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ARID5B | SNV | Missense_Mutation | novel | c.698N>A | p.Thr233Asn | p.T233N | Q14865 | protein_coding | deleterious(0) | possibly_damaging(0.899) | TCGA-E6-A2P9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARID5B | SNV | Missense_Mutation | rs550591609 | c.478G>A | p.Val160Ile | p.V160I | Q14865 | protein_coding | tolerated(0.24) | benign(0.027) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARID5B | SNV | Missense_Mutation | rs550591609 | c.478N>A | p.Val160Ile | p.V160I | Q14865 | protein_coding | tolerated(0.24) | benign(0.027) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARID5B | SNV | Missense_Mutation | rs747413904 | c.608N>T | p.Thr203Met | p.T203M | Q14865 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARID5B | SNV | Missense_Mutation | novel | c.1295N>C | p.Asn432Thr | p.N432T | Q14865 | protein_coding | tolerated(0.26) | benign(0.011) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |